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The incidence of myocardial infarction has been declining in the UK over the past 25 years, 1 2 but it varies between regions and still averages more than 600 hospitalised cases of ST-segment elevation myocardial infarction (STEMI) per million people each year. 3 4 The case fatality rates after myocardial infarction have also fallen, which has been attributed to improved access to effective treatments. 5 The over-riding priority in the management of STEMI is to restore coronary perfusion rapidly and effectively, thereby limiting the extent of damage to myocardium and reducing the likelihood of death or future heart failure. Coronary reperfusion can be achieved by fibrinolysis (with agents such as reteplase and tenecteplase) or by mechanical reopening of the occluded artery by angioplasty and stent insertion (primary percutaneous coronary intervention). This article summarises the most recent recommendations from the National Institute for Health and Care Excellence (NICE) on the delivery of effective and timely coronary reperfusion treatment for people with STEMI. 6 Recommendations NICE recommendations are based on systematic reviews of best available evidence and explicit consideration of cost effectiveness. When minimal evidence is available, recommendations are based on the guideline development group's experience and opinion of what constitutes good practice. Evidence levels for the recommendations are given in italics in square brackets. 
Assess eligibility for coronary perfusion therapy

Overcoming barriers
In 2008 the National Infarct Angioplasty Project, sponsored by the Department of Health, 9 determined that a national coronary reperfusion strategy of primary PCI was both feasible and cost effective compared with the previous strategy of delivering fibrinolysis. 10 Since then, implementation of a national primary angioplasty service in England has almost been completed with >90% of STEMI patients suitable for reperfusion therapy receiving primary PCI. 3 Increasing the percentage of patients receiving primary PCI will require increased access to services for those living in more rural areas, because of the challenges of transporting patients in a timely fashion. Some additional primary PCI centres are being commissioned in order to improve access, and greater use of air ambulances would also benefit these communities. Fibrinolysis will probably still be required for an important minority of patients, so paramedic skills within ambulance services serving these rural populations must be maintained. Configuration of PCI services must take account of the need for centres to undertake sufficient interventional procedures (not just primary PCI) in order to maintain centre and individual operator competence, and provide a "round the clock" primary PCI service. 
Further information on the guidance
The evidence base favouring the use of primary PCI over fibrinolysis is widely accepted, and the UK has moved in line with other European countries in delivering primary PCI services. The guideline also addresses other aspects of interventional practice that have varied, such as the approach to patients with STEMI who remain unconscious after resuscitation from cardiac arrest or those with cardiogenic shock, the site of arterial access (radial or femoral arteries), and the use of coronary thrombus extraction devices. The evidence base for several of these areas of practice is not robust, not least because of the difficulty undertaking randomised trials in the populations being considered (such as unconscious or haemodynamically unstable patients). However, this guideline has reviewed what evidence there is and attempted to provide consensus descriptions of best practice to help those providing these services.
Methods
The Guideline Development Group followed standard NICE methods in the development of this guideline (www.nice.org.uk/aboutnice/ howwework/developingniceclinicalguidelines/developing_nice_clinical_guidelines.jsp). The GDG comprised five consultant cardiologists (including the chair and deputy chair), a professor of resuscitation and prehospital emergency medicine, a consultant in emergency medicine, a consultant pharmacist, a consultant physician, a general practitioner, two lay members, a cardiac nurse, and a senior paramedic.
The group developed clinical questions; collected and appraised clinical evidence; and evaluated the cost effectiveness of proposed interventions and management strategies through literature review and economic analysis. The draft guideline went through a rigorous reviewing process, in which stakeholder organisations were invited to comment; the group took all comments into consideration when producing the final version of the guideline. Quality ratings of the evidence were based on the GRADE method (www.gradeworkinggroup. org). These relate to the quality of the available evidence for assessed outcomes rather than the quality of the clinical study. Where standard methods could not be applied, a customised quality assessment was undertaken. These were either presented as a narrative summary of the evidence or in customised GRADE tables (such as for meta-analysis of individual participant data).
NICE has produced three different versions of the guideline: a full version; a summary version, known as the "NICE guideline"; and a version for people who have had a STEMI, their family and carers, and the public. All these versions, as well as a pathway and a suite of tools to help implement the guideline, are available from the NICE website (http://guidance.nice.org.uk/CG167). Updates of the guideline will be produced as part of NICE's guideline development programme.
Future research
The guideline development group identified the following areas as needing further research:
• If a person with acute STEMI presents within 1 hour of the onset of symptoms, is it better for that person to be given fibrinolysis with a short call to needle time rather than be transferred to a centre that carries out primary PCI for primary PCI with a delay of up to 120 minutes?
• In people with acute STEMI who present more than 1 hour after the onset of symptoms, is the delay of 120-180 minutes for primary PCI associated with outcomes similar to, better than, or worse than prehospital fibrinolysis?
• What are the clinical effectiveness and cost effectiveness of radial arterial access compared with femoral arterial access for coronary angiography or primary PCI in people with acute STEMI managed by primary PCI?
• Does multivessel PCI, at the time of presentation of people with acute STEMI, confer an advantage over a strategy of "culprit vessel only" primary PCI, followed by further elective revascularisation driven by symptoms and evidence of ischaemia?
• What is the relationship between hospital volume of primary PCI procedures and optimal outcomes in people with acute STEMI?
